CollPlant Biotechnologies Ltd.
CLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.18 | 0.00 | -6.56 |
| FCF Yield | -35.35% | -5.11% | -16.25% | 0.66% |
| EV / EBITDA | -2.08 | -8.34 | -4.13 | 146.66 |
| Quality | ||||
| ROIC | -104.26% | -23.85% | -47.86% | 0.13% |
| Gross Margin | -417.09% | 71.78% | -393.65% | 87.18% |
| Cash Conversion Ratio | 0.85 | 0.39 | 0.81 | 10.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.87% | -11.18% | -63.48% | 88.97% |
| Free Cash Flow Growth | -292.14% | 75.17% | -1,495.34% | 121.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | 3.98 | 1.69 | -9.11 |
| Interest Coverage | -1,014.76 | -751.20 | -502.85 | 1.76 |
| Efficiency | ||||
| Inventory Turnover | 6.05 | 4.33 | 1.03 | 1.85 |
| Cash Conversion Cycle | 354.26 | -18.30 | 747.29 | 24.75 |